论文部分内容阅读
目的观察奥扎格雷钠与低分子肝素联合治疗进展性脑梗死的疗效及安全性。方法随机将急性进展性脑梗死患者112例分为治疗组和对照组各56例。对照组在临床常规治疗的基础上加用奥扎格雷钠80m g,静脉滴注,2次/d,连用14d;治疗组在对照组治疗方案的基础上再加用低分子肝素钠0.4mL皮下注射,2次/d,连用14d;治疗前、后依据美国国立卫生院卒中量表(N IHSS)评分及日常生活能力(B I)评分评定神经功能缺损程度,并监测肝肾功能、血尿常规、凝血4项及心电图。结果与对照组相比,治疗组N IHSS、B I评分在治疗后1、2周时差异具有统计学意义(P<0.05,P<0.01)。血小板、凝血酶原时间均在正常范围内;两组均未见明显不良反应。结论奥扎格雷钠与低分子肝素联合治疗进展性脑梗死疗效较好,使用安全。
Objective To observe the efficacy and safety of sodium ozagrel and low molecular weight heparin in the treatment of patients with progressive cerebral infarction. Methods Randomly divided 112 patients with acute progressive cerebral infarction into 56 cases in the treatment group and 56 cases in the control group. The control group was treated with Ozagrel sodium 80 m g intravenously, twice daily for 14 days on the basis of routine clinical treatment. The treatment group was treated with 0.4 mL of low molecular weight heparin sodium subcutaneously on the basis of the control group Injection, twice daily for 14 days. Before and after treatment, the degree of neurological deficit was assessed according to National Institutes of Health Stroke Scale (NHSS) score and daily living ability (BI) score. Liver and kidney function, hematuria, Coagulation 4 and ECG. Results Compared with the control group, the N IHSS and B I scores in the treatment group were statistically significant at 1 and 2 weeks after treatment (P <0.05, P <0.01). Platelets, prothrombin time are in the normal range; no obvious adverse reactions in both groups. Conclusion Ozagrel sodium and low molecular weight heparin combined therapy for advanced cerebral infarction is effective and safe to use.